Full-Time

Head of Global Supply Planning

Supply Chain

Updated on 8/23/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Up to 25% domestic and international travel required.

Bachelor's, Master's, PhD, Associate's

Category
Operations & Logistics (1)
Required Skills
Financial analysis

Get referred to Amgen

See people who can refer or advise you

Requirements
  • A minimum of 12–17 years of overall experience is required.
  • A doctorate degree and 2 years of directly related experience, or a master's degree and 4 years of directly related experience, or a bachelor's degree and 6 years of directly related experience, or an associate's degree and 10 years of directly related experience, or a high school diploma/GED and 12 years of directly related experience are required.
  • Experience supervising or leading direct reports is preferred.
  • A strong knowledge of advanced planning techniques related to demand and supply planning, financials, and network planning is required.
  • Strong knowledge of demand and supply planning, supply chain principles, and logistics is required.
  • Strong business analytical skills and company-wide knowledge are required.
  • Knowledge and understanding of financial analysis involving COGM, COGS, and NPV is required.
  • The candidate must be able to communicate across a wide range of staff levels and develop effective relationships in a matrix organization.
  • The candidate must be able to distill complex information into a logical, concise message for senior management.
  • Experience applying continuous improvement principles when designing, implementing, and sustaining supply chain solutions and projects is required.
Responsibilities
  • Lead a team of managers and senior associates responsible for orchestrating end-to-end global product supply plans and strategies.
  • Provide thought leadership for long-range scenarios and monthly planning cycles, and make decisions on business-critical lifecycle management and product strategy implementation.
  • Manage the consolidation of product supply risk for Operations Supply Governance.
  • Lead, coordinate, and present complex, multifaceted product and network supply chain scenario analyses for senior and executive management decision-making.
  • Monitor operational and tactical commercial supply planning performance using appropriate key performance indicators.
  • Lead and support special initiatives within the Global Supply Chain, including automation and artificial intelligence transformation initiatives.
  • Drive recruitment, hiring, and attrition management for the Global Product Supply Chain Planning team.
  • Enable business results through staff development, training, coaching, and team vision using a people-centered leadership style.
  • Manage, monitor, and modify the staff resource model to align with workload drivers and communicate staffing requirements.
  • Manage staff allocation of pipeline and inline products within the asset portfolio to ensure workload balance.
  • Deliver timely business support processes, including Temperature Excursion Forms, Quarterly Tax Reporting, the Annual Working Cell Bank Long Range Plan, and Product Master Data Integrity.
  • Interface across Supply Chain, Manufacturing, Finance, Regulatory, and Quality, summarizing and highlighting issues for executive management.
  • Share and develop best practices across the Global Supply Chain network to improve supply chain processes, systems, and procedures.
Desired Qualifications
  • Seven or more years of experience in a global pharmaceutical, biotechnology, or similar industry.
  • Detail-oriented, process-oriented, persevering, and independently capable of solving problems.
  • Outstanding communication capabilities and confidence dealing with all levels of management.
  • Knowledge of financial analysis involving COGM, COGS, and NPV.
  • Up to 25% domestic and international travel.
  • Subject-matter expertise in supply chain.
  • Experience guiding project design and implementation.
  • Experience maintaining supply chain expertise through professional conferences and researching industry developments and best practices.
  • Understanding of the end-to-end supply chain from raw material procurement through post-distribution monitoring.
  • Experience leading teams that contribute to supply chain goals.
  • Experience providing guidance to leadership on long-term strategy and objectives.
  • Experience leveraging Operational Excellence methodologies for continuous improvement.
  • Experience developing business proposals with high return on investment.
  • Ability to consider financial implications when making decisions and setting priorities.
  • Experience guiding successful completion of cross-site, cross-functional programs.
  • Ability to distill complex information into a logical, concise message for leadership.
  • Ability to write, review, and edit complex proposals for high-level decision-makers.
  • Experience leading decision-making on supply chain issues affecting a department.
  • Ability to anticipate network problems and partner on practical solutions.
  • Ability to adjust priorities quickly as situations change.
  • Experience building cross-functional teams using diverse staff capabilities.
  • Ability to promote team cohesiveness and camaraderie.
  • Ability to foster trust by acknowledging shortcomings and addressing them.
  • Experience working with business partners to build a vision, strategy, and goals.
  • Ability to facilitate conflict resolution among team members.
  • Ability to coach, mentor, and provide supply chain expertise to colleagues.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $10.1 billion, up 10%, and guidance rose to $39.4 billion.
  • Repatha, Evenity, and Uplizna surged 37%, 38%, and 90% in Q2 2026.
  • Amgen presented Repatha VESALIUS-CV data for ESC August 2026, expanding cardiovascular adoption.

What critics are saying

  • FDA proposed withdrawing Tavneos on April 27, 2026; EMA echoed revocation on June 26.
  • Prolia sales fell 32% in Q2 2026 as biosimilars attack Amgen’s legacy franchise.
  • Harbour BioMed won a June 2026 willful patent verdict; MariTide failure would crush growth.

What makes Amgen unique

  • Amgen’s portfolio spans cardiovascular, bone, immunology, oncology, and biosimilars.
  • MariTide targets monthly or less frequent obesity dosing, unlike weekly GLP-1 rivals.
  • Amgen runs seven research labs plus Hyderabad’s 2027 science and innovation center.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Aug 19th, 2026
Amgen surges 3.5% to $440 as healthcare stocks hit record high on strong Q2 results

Amgen shares jumped 3.5% to $440.08 on Wednesday as healthcare stocks reached record highs. The biotech company reported second-quarter revenue of $10.1 billion, up 10%, whilst GAAP earnings surged 65% to $4.37 per share. Twenty-two of Amgen's medicines posted double-digit sales growth, with seventeen products generating over $1 billion in annualised sales. Six key growth products climbed 26% and now account for nearly 70% of product revenue. The rally came as investors rotated into healthcare following excitement around Merck and Moderna's melanoma breakthrough. However, Amgen now trades at a 19% premium to its fair value estimate of $365.04, putting pressure on execution as some products like Prolia face headwinds.

Yahoo Finance
Aug 14th, 2026
Amgen and Regeneron emerge as GLP-1 investment alternatives beyond Eli Lilly and Novo Nordisk

Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.

PR Newswire
Aug 12th, 2026
Amgen to open new science and innovation centre in Hyderabad's Genome Valley

Amgen announced plans to open a new Science and Innovation Center in Genome Valley, Hyderabad, expected to be operational in 2027. The facility will join Amgen's global Research and Development network of seven research laboratories, expanding the company's scientific capabilities. The center will bring together scientists and technologists across discovery chemistry, drug metabolism and pharmacokinetics, and precision medicine. It will integrate experimental science with data and digital innovation to accelerate the discovery and development of medicines. "The new center in Genome Valley expands the way we integrate experimental science with data and technology across our global research capabilities," said Jay Bradner, executive vice president of Research and Development, Artificial Intelligence and Data at Amgen. The facility will complement Amgen's existing technology and innovation site in Hyderabad.

Yahoo Finance
Aug 9th, 2026
Amgen fair value rises to $372 after Q2 beat sparks analyst target hikes to $450

Amgen's modeled fair value has risen from $352.23 to $371.93 per share following strong Q2 results and updated analyst targets. Several firms, including Scotiabank, TD Cowen, BMO Capital, and Oppenheimer, lifted price targets to around $450, citing earnings revisions and a diversified product portfolio. Bernstein noted a 6.8% revenue beat and 12.5% non-GAAP EPS beat in Q2, with raised full-year guidance driven by portfolio-wide execution. Strength came from products including Repatha, Tezspire, Uplizna, Evenity, and Imdelltra. However, Wells Fargo and Citi maintain cautious stances with Equal Weight and Neutral ratings, suggesting current performance may already be priced in. BofA kept its Underperform rating, describing 2026 as focused on execution ahead of key 2027 readouts.

Yahoo Finance
Aug 5th, 2026
Amgen beats Q2 forecast with $10.05B revenue, raises 2026 outlook despite obesity drug setback

Amgen reported second-quarter revenue of $10.05 billion, up 9% year on year, beating Wall Street expectations. Adjusted earnings reached $6.29 per share, surpassing the $5.62 consensus estimate. The biotech firm raised its full-year 2026 outlook, increasing expected revenue to $38.2 billion-$39.4 billion from $37.0 billion-$38.4 billion. Adjusted earnings guidance rose to $22.30-$23.50 per share. Repatha sales surged 37% to $953 million, whilst Evenity jumped 38% to $714 million. Rare-disease therapy Uplizna saw roughly 90% growth. These gains offset a 32% decline in Prolia sales due to biosimilar competition. Amgen discontinued obesity candidate AMG 513 but continues developing MariTide, with Phase 3 data expected in 2027. The stock trades at $406.17, approximately 14.75% above its estimated fair value.